AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
IND Edition 
⚠
✓
Milestone Pharmaceuticals Inc (NASDAQ:MIST)
1.28 USD
-0.040 3.030%Sponsored Reports
Loading...
| Previous Close (in USD) | 1.32 |
|---|---|
| Change | -0.040 3.030% |
| 52 W H/L (in USD) | 4.100/1.330 |
| EBITDA (in USD) | -61.006M |
| PE Ratio | -- |
| Volume | 812645 |
| Diluted Eps TTM | -1.21 |
| Total Assets (in USD) | 75.226M |
|---|---|
| Total Liabilities (in USD) | 58.455M |
| Revenue TTM (in USD) | 1M |
| Cash (in USD) | 13.76M |
| Market Cap (in USD) | 87.880 M |
| Revenue Per Share TTM | 0.023 |
| Gross Profit TTM (in USD) | 5M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Dividend Paid
Milestone Pharmaceuticals Inc
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.
1111 Dr. Frederik-Philips Boulevard, Montreal, QC, Canada, H4M 2X6
514 336 0444
Employees: 47
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Mr. Joseph G. Oliveto M.B.A. | CEO, Pres & Director | 1968 |
| 2. | Mr. Amit Hasija | CFO & Exec. VP of Corp. Devel. | 1973 |
| 3. | Dr. Philippe Douville M.B.A., Ph.D. | Founder, Strategic Advisor & Member of Scientific Advisory Board | 1962 |
| 4. | Mr. Jeff Nelson | Chief Operating Officer | NA |
| 5. | Mr. Roshan Girglani | VP of Marketing | NA |
| 6. | Ms. Kimberly Sheehan | VP of HR | NA |
| 7. | Dr. Philip T. Sager FACC, FAHA, FHRS, M.D. | Chief Medical Advisor & Member of the Scientific Advisory Board | 1956 |
| 8. | Dr. Guy Rousseau | SVP of Regulatory Affairs and Quality Management | NA |
| 9. | Mr. Lorenz Muller | Chief Commercial Officer | 1964 |
| 10. | Dr. David B. Bharucha FACC, M.D., Ph.D. | Chief Medical Officer | 1962 |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
-0.920 2.144% | 42.715 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
-0.750 1.734% | 42.5 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
+3.250 0.765% | 420.63 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
+16.030 2.659% | 600.79 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Income Before Tax | -58.388M | -42.853M | -49.984M | -55.285M | -23.111M |
| Minority Interest | - | - | - | - | 0M |
| Net Income | -57.134M | -42.633M | -49.967M | -55.229M | -23.185M |
| Selling General Administrative | 15.718M | 12.399M | 10.285M | 7.004M | 3.052M |
| Gross Profit | 5M | 15M | - | - | 0M |
| Reconciled Depreciation | 0.089M | 0.093M | 0.097M | 0.038M | 0.01M |
| Ebit | -59.731M | -43.073M | -50.71M | -57.881M | -23.822M |
| Ebitda | -59.642M | -42.98M | -50.613M | -57.843M | -23.812M |
| Depreciation And Amortization | 0.089M | 0.093M | 0.097M | 0.038M | 0.01M |
| Operating Income | -59.642M | -43.073M | -50.71M | -57.881M | -23.822M |
| Other Operating Expenses | 64.642M | 58.073M | 50.71M | 57.881M | 23.822M |
| Interest Expense | -1.254M | 0.22M | 0.726M | 2.596M | 0M |
| Tax Provision | - | 0M | -0.017M | -0.056M | 0.074M |
| Interest Income | 1.254M | 0.22M | 0.726M | 2.596M | 0.711M |
| Net Interest Income | 1.254M | 0.22M | 0.726M | 2.596M | 0.711M |
| Income Tax Expense | -1.254M | -0.22M | -0.017M | -0.056M | 0.074M |
| Total Revenue | 5M | 15M | 0M | 0M | 0M |
| Total Operating Expenses | 64.642M | 58.073M | 50.71M | 57.881M | 23.822M |
| Cost Of Revenue | - | - | - | - | 0M |
| Total Other Income Expense Net | 1.254M | 0.22M | 0.726M | 2.596M | 0.711M |
| Net Income From Continuing Ops | -58.388M | -42.853M | -49.967M | -55.229M | -23.185M |
| Net Income Applicable To Common Shares | -58.388M | -42.853M | -49.967M | -55.229M | -23.185M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 75.226M | 74.483M | 119.849M | 149.974M | 123.428M |
| Intangible Assets | - | - | - | - | - |
| Other Current Assets | 3.178M | 6.336M | 4.655M | 6.153M | 2.423M |
| Total Liab | 58.455M | 8.135M | 7.249M | 6.855M | 8.511M |
| Total Stockholder Equity | 16.771M | 66.348M | 112.6M | 143.119M | 114.917M |
| Other Current Liab | 2.699M | 3.381M | 2.167M | 1.273M | 3.621M |
| Common Stock | 260.504M | 273.9M | 251.901M | 251.682M | 226.245M |
| Capital Stock | 260.504M | 273.9M | 251.901M | 251.682M | 226.245M |
| Retained Earnings | -326.026M | -266.341M | -206.319M | -163.466M | -113.499M |
| Good Will | - | - | - | - | - |
| Other Assets | - | - | - | - | - |
| Cash | 13.76M | 7.636M | 114.141M | 72.31M | 119.818M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 7.226M | 6.139M | 6.775M | 6.159M | 8.327M |
| Current Deferred Revenue | - | - | - | - | - |
| Net Debt | 38.015M | -5.145M | -113.443M | -71.369M | -119.304M |
| Short Term Debt | 0.546M | 0.495M | 0.224M | 0.245M | 0.33M |
| Short Long Term Debt | - | - | - | - | - |
| Short Long Term Debt Total | 51.775M | 2.491M | 0.698M | 0.941M | 0.514M |
| Other Stockholder Equity | 33.834M | 58.789M | 68.652M | 56.537M | 3.805M |
| Property Plant Equipment | - | 2.68M | 0.215M | 1.288M | 0.929M |
| Total Current Assets | 73.032M | 71.803M | 118.923M | 148.686M | 122.499M |
| Long Term Investments | - | - | - | - | - |
| Short Term Investments | 52.243M | 56.949M | - | 70M | - |
| Net Receivables | 3.851M | 1.213M | 0.483M | 0.948M | 0.836M |
| Long Term Debt | 49.772M | - | - | - | - |
| Inventory | - | -0.331M | -0.356M | -0.725M | -0.578M |
| Accounts Payable | 3.981M | 2.263M | 4.384M | 4.641M | 4.376M |
| Accumulated Other Comprehensive Income | 48.459M | - | -1.634M | -1.634M | -1.634M |
| Non Currrent Assets Other | - | - | 0.711M | 0.98M | 0.929M |
| Non Current Assets Total | 2.194M | 2.68M | 0.926M | 1.288M | 0.929M |
| Capital Lease Obligations | 2.003M | 2.491M | 0.698M | 0.941M | 0.514M |
| Long Term Debt Total | - | - | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Investments | -57.124M | 70M | -70M | -0.384M | 16.003M |
| Total Cashflows From Investing Activities | -57.124M | 70M | -70M | -0.384M | 15.998M |
| Total Cash From Financing Activities | 3.088M | 5.055M | 73.224M | 85.407M | 80.115M |
| Net Income | -58.388M | -42.853M | -49.967M | -55.229M | -23.185M |
| Change In Cash | -106.505M | 41.831M | -47.508M | 33.871M | 75.067M |
| Begin Period Cash Flow | 114.141M | 72.31M | 119.818M | 85.947M | 10.88M |
| End Period Cash Flow | 7.636M | 114.141M | 72.31M | 119.818M | 85.947M |
| Total Cash From Operating Activities | -52.469M | -33.224M | -50.732M | -51.152M | -21.046M |
| Depreciation | 0.089M | 0.093M | 0.097M | 0.038M | 0.01M |
| Other Cashflows From Investing Activities | - | - | - | 0.029M | 16.003M |
| Dividends Paid | - | - | - | - | 0M |
| Change To Inventory | - | - | - | - | 0M |
| Sale Purchase Of Stock | - | 0.121M | 48.453M | 85.407M | 80.461M |
| Other Cashflows From Financing Activities | 0.458M | 5.055M | 48.307M | 0.044M | 80.115M |
| Capital Expenditures | 0.272M | 0M | 0.097M | 0.413M | 0.005M |
| Change In Working Capital | -3.262M | 2.257M | -5.807M | 2.848M | 1.496M |
| Other Non Cash Items | 0.044M | 32.636M | -34.162M | -27.806M | -56.072M |
| Free Cash Flow | -52.741M | -33.224M | -50.732M | -51.565M | -21.051M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Dimensional Global Sust Cor Eq USD Acc | 2 years ago | 2700 |
| 2. | Dimensional World Allc 60/40 GBP Acc | 2 years ago | 2602 |
| 3. | DFA US Core Equity Class F | 2 years ago | 1688 |
| 4. | JNL/DFA US Small Cap A | 2 years ago | 1661 |
| 5. | Dimensional International Core Eq Acc | 2 years ago | 1600 |
| 6. | Dimensional US Sm Company EUR Acc | 2 years ago | 1433 |
| 7. | Dimensional US Small Cap CIT Class S | 2 years ago | 573 |
| 8. | LUNIS Biotech Growth Opp Fd I a | 2 years ago | 26900 |
| 9. | BC Biotech S | 2 years ago | 20000 |
| 10. | SPDR® S&P International Small Cap ETF | 2 years ago | 18923 |
| 11. | Fidelity Nasdaq Composite Index | 2 years ago | 17576 |
| 12. | Dimensional Global Core Equity USD Acc | 2 years ago | 5869 |
| 13. | Dimensional Global Small Coms USD Acc | 2 years ago | 5016 |
| 14. | Dimensional World Equity GBP Acc | 2 years ago | 3650 |
| 15. | Dimensional Global Sust Cor Eq USD Acc | 2 years ago | 2700 |
| 16. | Dimensional World Allc 60/40 GBP Acc | 2 years ago | 2602 |
| 17. | JNL/DFA US Small Cap A | 2 years ago | 1661 |
| 18. | Dimensional International Core Eq Acc | 2 years ago | 1600 |
| 19. | Dimensional US Sm Company EUR Acc | 2 years ago | 1433 |
| 20. | Dimensional US Small Cap CIT Class S | 2 years ago | 1146 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | BlackRock Inc | 2 years ago | 3270749 |
| 2. | RTW INVESTMENTS, LLC | 2 years ago | 3256102 |
| 3. | Millennium Management LLC | 2 years ago | 2855612 |
| 4. | Goldman Sachs Group Inc | 2 years ago | 2706134 |
| 5. | Alta Fundamental Advisers LLC | 2 years ago | 2371289 |
| 6. | Lion Point Capital, LP | 2 years ago | 2300207 |
| 7. | Orbimed Advisors, LLC | 2 years ago | 2000000 |
| 8. | Nantahala Capital Management, LLC | 2 years ago | 1750000 |
| 9. | Stonepine Capital Management Llc | 2 years ago | 1462296 |
| 10. | Bleichroeder LP | 2 years ago | 1326085 |
| 11. | Morgan Stanley - Brokerage Accounts | 2 years ago | 689400 |
| 12. | Velan Capital Investment Management LP | 2 years ago | 650000 |
| 13. | BML Capital Management LLC | 2 years ago | 606145 |
| 14. | Ikarian Capital, LLC | 2 years ago | 466019 |
| 15. | Boxer Capital LLC | 2 years ago | 309007 |
| 16. | Barclays PLC | 2 years ago | 255185 |
| 17. | Ancora Advisors LLC | 2 years ago | 50000 |
| 18. | Dimensional Fund Advisors, Inc. | 2 years ago | 39450 |
| 19. | Northern Trust Corp | 2 years ago | 31970 |
| 20. | BOOTHBAY FUND MANAGEMENT, LLC | 2 years ago | 27588 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...